Literature DB >> 26788280

T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Presenting as a Primary Central Nervous System Lymphoma.

Pooja Advani1, Jason Starr2, Abhisek Swaika1, Liuyan Jiang3, Yushi Qiu4, Zhimin Li4, Han W Tun5.   

Abstract

Primary central nervous system (PCNSL) lymphoma is an aggressive extranodal non-Hodgkin lymphoma, and most cases are classified as diffuse large B-cell lymphoma (DLBCL) by histology. T-cell/histiocyte-rich large B-cell lymphoma (TCRLBCL) represents a distinct subtype of diffuse large B-cell lymphoma and is characterized by the presence of scattered large neoplastic B-cells in a background of abundant T-cells and histiocytes. This is in contrast to the dense perivascular cuffing of neoplastic B-cells in classic DLBCL. T-cell/histiocyte-rich large B-cell lymphoma should be considered in PCNSL cases in which neoplastic B-cells are sparse and scattered. Immunohistochemistry will help identify the B-cells and surrounding infiltrate rich in Tlymphocytes and histiocytes. Future studies exploring the biology of TCRLBCL and the crosstalk between the neoplastic cells and the surrounding inflammatory infiltrate may provide exciting prospects for future therapies for TCRLBCL.

Entities:  

Keywords:  Central nervous system; T-cell/histiocyte-rich large B-cell lymphoma; diffuse large B-cell lymphoma; osteopontin

Year:  2015        PMID: 26788280      PMCID: PMC4703926          DOI: 10.4081/rt.2015.6084

Source DB:  PubMed          Journal:  Rare Tumors        ISSN: 2036-3605


  10 in total

1.  Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma.

Authors:  Liuyan Jiang; Zhimin Li; Laura E Finn; David A Personnet; Brandy Edenfield; James M Foran; Kurt A Jaeckle; Ronald Reimer; David M Menke; Rhett P Ketterling; Han W Tun
Journal:  Int J Clin Exp Pathol       Date:  2012-01-01

Review 2.  Pathology of primary central nervous system lymphoma.

Authors:  Deborah L Commins
Journal:  Neurosurg Focus       Date:  2006-11-15       Impact factor: 4.047

3.  Differential gene expression in central nervous system lymphoma.

Authors:  James L Rubenstein; Arthur Shen; Tracy T Batchelor; Cigall Kadoch; Patrick Treseler; Marc A Shuman
Journal:  Blood       Date:  2009-01-01       Impact factor: 22.113

4.  How I treat primary CNS lymphoma.

Authors:  Andrés J M Ferreri
Journal:  Blood       Date:  2011-05-25       Impact factor: 22.113

5.  T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis.

Authors:  R Bouabdallah; N Mounier; C Guettier; T Molina; V Ribrag; C Thieblemont; A Sonet; A Delmer; K Belhadj; P Gaulard; C Gisselbrecht; L Xerri
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

6.  T-cell/histiocyte-rich large B-cell lymphoma: a distinct clinicopathologic entity.

Authors:  R Achten; G Verhoef; L Vanuytsel; C De Wolf-Peeters
Journal:  J Clin Oncol       Date:  2002-03-01       Impact factor: 44.544

Review 7.  T-cell/histiocyte-rich B-cell lymphoma: biology, diagnosis, and management.

Authors:  Jeremy S Abramson
Journal:  Oncologist       Date:  2006-04

Review 8.  Primary central nervous system lymphoma.

Authors:  Sharathkumar Bhagavathi; Jon D Wilson
Journal:  Arch Pathol Lab Med       Date:  2008-11       Impact factor: 5.534

9.  Pathway analysis of primary central nervous system lymphoma.

Authors:  Han W Tun; David Personett; Karen A Baskerville; David M Menke; Kurt A Jaeckle; Pamela Kreinest; Brandy Edenfield; Abba C Zubair; Brian P O'Neill; Weil R Lai; Peter J Park; Michael McKinney
Journal:  Blood       Date:  2008-01-09       Impact factor: 22.113

10.  Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models.

Authors:  Zhimin Li; Yushi Qiu; David Personett; Peng Huang; Brandy Edenfield; Jason Katz; Darius Babusis; Yang Tang; Michael A Shirely; Mehran F Moghaddam; John A Copland; Han W Tun
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.